Literature DB >> 19959684

Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx.

Susan T Mayne1, Brenda Cartmel, Victoria Kirsh, W Jarrard Goodwin.   

Abstract

As more people begin to survive first cancers, there is an increased need for science-based recommendations to improve survivorship. For survivors of head and neck cancer, use of tobacco and alcohol before diagnosis predicts poorer survival; however, the role of continuing these behaviors after diagnosis on mortality is less clear, especially for more moderate alcohol consumption. Patients (n = 264) who were recent survivors of early stage head and neck cancer were asked to retrospectively report their tobacco and alcohol histories (before diagnosis), with information prospectively updated annually thereafter. Patients were followed for an average of 4.2 years, with 62 deaths observed. Smoking history before diagnosis dose-dependently increased the risk of dying; risks reached 5.4 [95% confidence interval (95% CI), 0.7-40.1] among those with >60 pack-years of smoking. Likewise, alcohol history before diagnosis dose-dependently increased mortality risk; risks reached 4.9 (95% CI, 1.5-16.3) for persons who drank >5 drinks/d, an effect explained by beer and liquor consumption. After adjusting for prediagnosis exposures, continued drinking (average of 2.3 drinks/d) postdiagnosis significantly increased risk (relative risk for continued drinking versus no drinking, 2.7; 95% CI, 1.2-6.1), whereas continued smoking was associated with nonsignificantly higher risk (relative risk for continued smoking versus no smoking, 1.8; 95% CI, 0.9-3.9). Continued drinking of alcoholic beverages after an initial diagnosis of head and neck cancer adversely affects survival; cessation efforts should be incorporated into survivorship care of these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959684      PMCID: PMC2789339          DOI: 10.1158/1055-9965.EPI-09-0944

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  20 in total

1.  Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia.

Authors:  M D Gammon; J B Schoenberg; H Ahsan; H A Risch; T L Vaughan; W H Chow; H Rotterdam; A B West; R Dubrow; J L Stanford; S T Mayne; D C Farrow; S Niwa; W J Blot; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1997-09-03       Impact factor: 13.506

Review 2.  Second primary malignancies in the head and neck cancer patient.

Authors:  E M Sturgis; R H Miller
Journal:  Ann Otol Rhinol Laryngol       Date:  1995-12       Impact factor: 1.547

3.  Mortality in relation to smoking: 40 years' observations on male British doctors.

Authors:  R Doll; R Peto; K Wheatley; R Gray; I Sutherland
Journal:  BMJ       Date:  1994-10-08

Review 4.  Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience.

Authors:  J S Cooper; T F Pajak; P Rubin; L Tupchong; L W Brady; S A Leibel; G E Laramore; V A Marcial; L W Davis; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-09       Impact factor: 7.038

5.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

6.  Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Authors:  Fadlo R Khuri; J Jack Lee; Scott M Lippman; Edward S Kim; Jay S Cooper; Steven E Benner; Rodger Winn; Thomas F Pajak; Brendell Williams; George Shenouda; Ian Hodson; Karen Fu; Dong M Shin; Everett E Vokes; Lei Feng; Helmuth Goepfert; Waun Ki Hong
Journal:  J Natl Cancer Inst       Date:  2006-04-05       Impact factor: 13.506

7.  Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol.

Authors:  G L Day; W J Blot; R E Shore; J K McLaughlin; D F Austin; R S Greenberg; J M Liff; S Preston-Martin; S Sarkar; J B Schoenberg
Journal:  J Natl Cancer Inst       Date:  1994-01-19       Impact factor: 13.506

8.  Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study.

Authors:  M Bolla; R Lefur; J Ton Van; C Domenge; J M Badet; Y Koskas; A Laplanche
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

9.  Alcoholism: independent predictor of survival in patients with head and neck cancer.

Authors:  F W Deleyiannis; D B Thomas; T L Vaughan; S Davis
Journal:  J Natl Cancer Inst       Date:  1996-04-17       Impact factor: 13.506

10.  Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors.

Authors:  R Doll; R Peto; E Hall; K Wheatley; R Gray
Journal:  BMJ       Date:  1994-10-08
View more
  54 in total

Review 1.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

2.  MicroRNA-Related Genetic Variants Associated with Survival of Head and Neck Squamous Cell Carcinoma.

Authors:  Owen M Wilkins; Alexander J Titus; Lucas A Salas; Jiang Gui; Melissa Eliot; Rondi A Butler; Erich M Sturgis; Guojun Li; Karl T Kelsey; Brock C Christensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-06-07       Impact factor: 4.254

3.  Impact of dietary vitamin D on initiation and progression of oral cancer.

Authors:  Aparajita Verma; Vui King Vincent-Chong; Hendrik DeJong; Pamela A Hershberger; Mukund Seshadri
Journal:  J Steroid Biochem Mol Biol       Date:  2020-01-22       Impact factor: 4.292

4.  Long-term workforce participation patterns following head and neck cancer.

Authors:  Alison Pearce; Aileen Timmons; Eleanor O'Sullivan; Pamela Gallagher; Rachael Gooberman-Hill; Audrey Alforque Thomas; Michal Molcho; Phyllis Butow; Linda Sharp
Journal:  J Cancer Surviv       Date:  2014-07-25       Impact factor: 4.442

5.  Maximizing benefits for effective cancer survivorship programming: defining a dissemination and implementation plan.

Authors:  Kathleen Y Wolin; Graham A Colditz; Enola K Proctor
Journal:  Oncologist       Date:  2011-07-17

Review 6.  Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions.

Authors:  Joshua D Smith; Andrew G Shuman; Michelle B Riba
Journal:  Curr Psychiatry Rep       Date:  2017-09       Impact factor: 5.285

7.  Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer.

Authors:  Ding Ding; William Stokes; Megan Eguchi; Mohammad Hararah; Whitney Sumner; Arya Amini; Julie Goddard; Hilary Somerset; Cathy Bradley; Jessica McDermott; David Raben; Sana D Karam
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-01-01       Impact factor: 6.223

Review 8.  Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research.

Authors:  Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-17       Impact factor: 4.254

9.  Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients.

Authors:  Graham W Warren; James R Marshall; K Michael Cummings; Benjamin Toll; Ellen R Gritz; Alan Hutson; Seyedeh Dibaj; Roy Herbst; Carolyn Dresler
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

10.  Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.

Authors:  Jesse D Troy; Joel L Weissfeld; Brenda Diergaarde; Ada O Youk; Shama C Buch; Marjorie Romkes; Jennifer R Grandis
Journal:  Cancer Epidemiol       Date:  2013-03-21       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.